Stablizing An Enzyme By Forming A Mixture, An Adduct Or A Composition, Or Formation Of An Adduct Or Enzyme Conjugate Patents (Class 435/188)
-
Publication number: 20140072515Abstract: Compounds used as labels with properties comparable to known fluorescent compounds. The compounds can be conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided.Type: ApplicationFiled: February 28, 2013Publication date: March 13, 2014Inventors: Greg Hermanson, Peter T. Czerney, Surbhi Desai, Matthias S. Wenzel, Boguslawa R. Dworecki, Frank G. Lehmann, Marie Christine Nlend
-
Publication number: 20140072594Abstract: The present invention encompasses vaccines or compositions comprising the chimeric KSAC protein that possesses immunogenic and protective properties, and methods of use including administering to an animal the antigenic KSAC protein thereof to protect animals. The invention also encompasses methods for making and producing the soluble, disaggregated, refolded or active proteins from inclusion bodies produced from prokaryotes or eukaryotes.Type: ApplicationFiled: August 30, 2013Publication date: March 13, 2014Applicant: MERIAL LIMITEDInventors: Laurent Bernard Fischer, Nicolas Pierre Yves Carboulec, Fabien Lux
-
Publication number: 20140072961Abstract: The use of P2E2 constructs in genome surgery includes a cell penetration component, a DNA binding component and a restriction endonuclease. The method for performing genome surgery includes: a) providing one or more recombinant of the P2E2 constructs; b) penetrating a cell with the recombinant P2E2 protein construct; c) forming a protein product in the cell by the processes of transcription and translation or by direct introduction of the P2E2 protein construct to the cell; d) attaching the protein product of the P2E2 construct to one or more targeted genomic sequences within the cell; and e) the endonuclease of the P2E2 construct cutting both strands of the genome at target locations.Type: ApplicationFiled: July 9, 2013Publication date: March 13, 2014Inventors: Martin Schiller, Christy Strong
-
Publication number: 20140073030Abstract: The present compositions and methods relate to an endo-?-mannanase cloned from Bacillus agaradhaerens, polynucleotides encoding the endo-?-mannanase, and methods of use thereof. Formulations containing the endo-?-mannanase are highly suitable for use as detergents.Type: ApplicationFiled: April 27, 2012Publication date: March 13, 2014Applicant: Danisco US Inc.Inventors: Brian E. Jones, Marc Kolkman, Zhen Qian, Brian Sogaard Laursen, Karsten M. Kragh, Sina Pricelius, Zheyong Yu, Lilian Maria Babe, Melodie Estabrook
-
Publication number: 20140073548Abstract: The present compositions and methods relate to an endo-B-mannanase cloned from a Bacillus sp., polynucleotides encoding the endo-B-mannanase, and methods of use thereof. Formulations containing the endo-?-mannanase are highly suitable for use as detergents.Type: ApplicationFiled: April 27, 2012Publication date: March 13, 2014Applicant: Danisco US Inc.Inventors: Brian E. Jones, Marc Kolkman, Zhen Qian, Brian Sogaard Laursen, Karsten M. Kragh, Sina Pricelius, Zheyong Yu, Lilia Maria Babe, Melodie Estabrook, Ling Hua
-
Publication number: 20140065175Abstract: The invention relates to the technological sector of the transport and delivery of molecules into cells, either at cytoplasm or at nucleus or inter-cells (cell to cell transport), using peptides binding proteins from the cell microtubule motor complex, preferably dynein-binding peptides, as carrier/delivery peptides; or functionalized structures, as nanoparticles, linked to said carrier/delivery peptides. This delivery can be useful in many technical fields comprising, among some others: diagnosis, therapy and pharmacology.Type: ApplicationFiled: February 17, 2012Publication date: March 6, 2014Inventors: M. Covadonga Alonso Martí, José Ángel Martínez Escribano
-
Publication number: 20140065064Abstract: Monoclonal antibodies (MoAbs or mAbs) specific for ALPHA-ACTININ-4 antigens, hybridoma lines that secrete these ALPHA-ACTININ-4 mAbs, and the use of such mAbs to detect ALPHA-ACTININ-4 antigens, particularly those expressed by cancer cells are disclosed. Chimeric and humanized antibodies based upon these anti-ALPHA-ACTININ-4 mAbs, processes for producing monoclonal, chimeric, and humanized antibodies using recombinant DNA technology, and their therapeutic uses, particularly in the treatment of cancer are also disclosed. Methods and kits for the immunodetection and immunotherapy of cells for samples which express ALPHA-ACTININ-4 antigens are additionally disclosed.Type: ApplicationFiled: December 23, 2011Publication date: March 6, 2014Inventor: Özge Alper
-
Publication number: 20140065123Abstract: Provided are a PEGylated analogue protein of canine urate oxidase, preparation method and use thereof. The analogue protein of canine urate oxidase is a canine urate oxidase, or a chimeric protein comprising part of the amino acid sequence of a canine urate oxidase and part of the amino acid sequence of a human urate oxidase, or a mutant protein thereof. The PEGylated analogue protein of canine urate oxidase and pharmaceutical compositions thereof according to the present invention can be used for the prevention and/or treatment of hyperuricemia and chronic gout.Type: ApplicationFiled: February 14, 2012Publication date: March 6, 2014Applicant: Chongqing Fagen Biomedical Inc. No. 80 4th Street KeyuanInventors: Chun Zhang, Kai Fan, Xuefeng Ma, Li Yang, Chunlan Hu, Hua Luo, Xiang Mei
-
Publication number: 20140065183Abstract: The present invention is directed to an acyl homoserine lactone and catalase conjugate wherein the acyl homoserine lactone is N-3-(oxododecanoyl)-L-homoserine lactone (OdDHL) or butyryl L-homoserine lactone (BHL) and the catalase is a P. aeruginosa KatA protein or an antigenic portion thereof. The conjugate is used to treat P. aeruginosa infections by limiting the formation of biofilms and inhibiting a range of quorum-sensing dependent virulence factors by having an immunogenic conjugate provided as a therapeutic or prophylactic vaccine.Type: ApplicationFiled: December 23, 2011Publication date: March 6, 2014Applicant: Central Queensland UniversityInventors: Jennelle M. Kyd, Margaret Cooley
-
Patent number: 8663961Abstract: Disclosed herein are compounds, including compounds having the structure of Formula (A), (B), (C), and (D), as described in further detail herein, that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.Type: GrantFiled: May 15, 2012Date of Patent: March 4, 2014Assignee: Pharmacyclics, Inc.Inventors: Lee Honigberg, Erik Verner, Zhengying Pan
-
Patent number: 8663616Abstract: Disclosed herein are compositions and methods to treat an oral cavity surface with a peracid-based benefit agent. The peracid benefit agent can be use for oral surface bleaching, whitening, disinfecting, destaining, deodorizing, decreasing or removing biofilm, and combinations thereof. The peracid is enzymatically generated from a carboxylic acid ester substrate using a CE-7 carbohydrate esterase having perhydrolytic activity (perhydrolase) in the presence of a source of peroxygen. A fusion protein comprising the perhydrolase coupled to a peptidic component having affinity for an oral cavity surface, either directly or through an optional linker, may be used to target the perhydrolytic activity to the oral cavity surface.Type: GrantFiled: December 19, 2011Date of Patent: March 4, 2014Assignee: E I du Pont de Nemours and CompanyInventors: Lisa A. Butterick, Scott D. Cunningham, Robert DiCosimo, Kari A. Fosser, Tanja Maria Gruber, Sharon L. Haynie, Mark S. Payne, Pierre E. Rouviere, Hong Wang
-
Publication number: 20140057284Abstract: The invention concerns novel molecular complexes with photoluminescent probes whose specific association with purine-binding proteins leads to increased emission of long lifetime luminescence, and the application of the probes for monitoring activity of protein kinases (PKs) and other purine-binding proteins, screening of compounds as inhibitors of PKs and characterization of inhibitors targeted to the kinase, and methods of manufacturing of such probes. The invention concerns also the use of the improved method for monitoring activity of protein kinases in living cells, characterization of inhibitors of protein kinases, analysis of protein kinase-based disease biomarkers and other tasks of biological and medical importance.Type: ApplicationFiled: January 26, 2012Publication date: February 27, 2014Applicant: UNIVERSITY OF TARTUInventors: Asko Uri, Erki Enkvist, Angela Vaasa, Marje Kasari
-
Publication number: 20140056867Abstract: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.Type: ApplicationFiled: June 18, 2013Publication date: February 27, 2014Applicant: BIOMARIN PHARMACEUTICALInventors: Jonathan LeBowitz, Stephen M. Beverley
-
Publication number: 20140050713Abstract: Provided herein are antibacterial compositions and methods of making and using the compositions.Type: ApplicationFiled: April 12, 2012Publication date: February 20, 2014Inventors: C.B. Appaiah, Sriram Padmanabhan, R. Sanjeev Saravanan, Bharathi Sriram
-
Publication number: 20140051145Abstract: The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.Type: ApplicationFiled: October 26, 2012Publication date: February 20, 2014Applicant: Agensys, Inc.Inventors: Aya JAKOBOVITS, Robert Kendall Morrison, Arthur B. Raitano, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen Jane Meyrick Morrison, Mary Faris, Wangmao Ge, Jean Gudas, Steven B. Kanner
-
Publication number: 20140050754Abstract: The present invention relates to immunogenic peptides of Chikungunya Virus and methods for vaccinating a subject using these peptides. Also disclosed are nucleic acids encoding these peptides and methods for their production.Type: ApplicationFiled: December 12, 2011Publication date: February 20, 2014Applicants: NATIONAL HEALTHCARE GROUP PTE LTD, AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Joo Chuan Tong, Jin Kiat Wee, Fong Poh Lisa Ng, Yiu-Wing Jason Kam, Yee Sin Leo, Angela Chow
-
Publication number: 20140050666Abstract: The present invention relates to a composition comprising a lysosomal enzyme conjugated to a negatively charged scavenger receptor ligand. In some embodiments, the lysosomal enzyme is conjugated to the scavenger receptor ligand by way of a linker. The present invention also relates to a composition comprising lysosomal enzyme encapsulated by a liposome, said liposome externally comprising a negatively charged scavenger receptor ligand. The invention further encompasses a method of treating a lysosomal storage disease with the compositions listed above. The invention further encompasses a method of treating a lysosomal storage disease with an acylated, acetylated, or aconitylated lysosomal enzyme.Type: ApplicationFiled: August 19, 2013Publication date: February 20, 2014Applicant: RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORKInventors: David H. Calhoun, Lane Gilchrist
-
Publication number: 20140051645Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) also known as CD152, which proteins preferably are muteins of a lipocalin protein, more preferably of lipocalin 2 (Lcn2 or NGAL). The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such lipocalin proteins, including uses of these proteins.Type: ApplicationFiled: December 2, 2011Publication date: February 20, 2014Inventors: Gabriele Matschiner, Andreas Hohlbaum, Arne Skerra
-
Publication number: 20140051708Abstract: The present invention relates to pyrazolyl-pyrimidine derivatives which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such compounds or the pharmaceutical compositions containing them.Type: ApplicationFiled: April 3, 2012Publication date: February 20, 2014Applicant: NERVIANO MEDICAL SCIENCES S.R.L.Inventors: Francesco Casuscelli, Maria Gabriella Brasca, Marina Caldarelli, Giovanni Cervi, Teresa Disingrini, Francesca Quartieri
-
Patent number: 8652484Abstract: The present invention relates to methods and compositions for pretargeting delivery of therapeutic agents. In preferred embodiments, the pretargeting method comprises: a) administering a bispecific antibody with a first binding site for a disease-associated antigen and a hapten on a targetable construct; b) administering a targetable construct comprising at least one therapeutic agent. In preferred embodiments, the bispecific antibody is made by the dock-and-lock (DNL) technique. In a more preferred embodiment, the targetable construct comprises one or more SN-38 moieties.Type: GrantFiled: December 11, 2012Date of Patent: February 18, 2014Assignee: Immunomedics, Inc.Inventors: William J. McBride, Christopher A. D'Souza, Chien-Hsing Chang, David M. Goldenberg
-
Patent number: 8652301Abstract: A method is provided for controlling organic contaminants, such as xylans, pitch or both, that interfere with bleaching of fibers and/or cause other interference(s) in papermaking systems. The method includes contacting fibers before any bleaching thereof with a composition which contains a hemicellulolytic enzyme and an organic contaminant removal adjuvant to liberate the organic contaminants from the fibers. The treated fibers can then be bleached and further used, for example, in making paper. The present invention also relates to the treatment compositions and to paper products made with fiber materials treated with these compositions. A method of enhancing enzymatic degradation of a substrate as well as formulations and systems for achieving the same are also provided. Various substrates can be degraded or otherwise processed, including biomass, paper mill sludge, and animal hides. Enzymatic degradation can be enhanced by including one or more polymeric surfactants.Type: GrantFiled: October 26, 2012Date of Patent: February 18, 2014Assignee: Buckman Laboratories International, Inc.Inventors: Stephen D. Bryant, Kevin J. MacDonald, Bernard Janse, Xiangdong Zhou, Philip Hoekstra, Daniel E. Glover
-
Patent number: 8652455Abstract: Disclosed herein are compositions and methods to target enzymatic peracid production to a target surface. The peracid benefit agent produced by the targeted perhydrolytic enzyme can be use for a variety of applications such as bleaching, whitening, disinfecting, destaining, deodorizing, and combinations thereof. Specifically, a fusion protein comprising a perhydrolytic enzyme and at least one peptidic component having affinity for a target surface (excluding body surfaces and oral care surfaces) is used in combination with a suitable substrate and a source of peroxygen to enzymatically produce a peracid on or near the surface of the target material. In a preferred aspect, the target surface is a cellulosic material.Type: GrantFiled: December 19, 2011Date of Patent: February 18, 2014Assignee: E I du Pont de Nemours and CompanyInventors: Robert DiCosimo, Scott D. Cunningham, Stephen R. Fahnestock, Tanja Maria Gruber, Mark S. Payne, Pierre E. Rouviere, Linda Jane Solomon, Hong Wang
-
Publication number: 20140044714Abstract: Described herein is the identification of human monoclonal antibodies that bind GPC3 or heparan sulfate (HS) chains on GPC3 with high affinity. The antibodies described herein are capable of inhibiting HCC cell growth and migration. Provided are human monoclonal antibodies specific for GPC3 or HS chains on GPC3, including immunoglobulin molecules, such as IgG antibodies, as well as antibody fragments, such as single-domain VH antibodies or single chain variable fragments (scFv). Further provided are compositions including the antibodies that bind GPC3 or HS chains on GPC3, nucleic acid molecules encoding these antibodies, expression vectors comprising the nucleic acids, and isolated host cells that express the nucleic acids. Methods of treating cancer and/or inhibiting tumor growth or metastasis are also provided. Further provided are methods of detecting cancer in a subject and confirming a diagnosis of cancer in a subject.Type: ApplicationFiled: April 19, 2012Publication date: February 13, 2014Inventors: Mitchell Ho, Mingqian Feng, Wei Gao, Heungnam Kim, Dimiter S. Dimitrov
-
Publication number: 20140045216Abstract: Polypeptide signal sequences of modified fragments of human immunoglobulin heavy chain binding protein (Bip) are disclosed. Also disclosed are fusion proteins comprising a modified fragment of human immunoglobulin heavy chain binding protein (Bip) operably linked to a heterologous polypeptide. Also disclosed are protein expression vectors comprising a promoter operably linked to a first DNA sequence encoding a signal sequence comprising a modified fragment of human immunoglobulin heavy chain binding protein (Bip) and a second DNA sequence encoding a heterologous polypeptide fused in frame to the first DNA sequence. Further disclosed are methods of producing a polypeptide comprising expressing a fusion protein comprising a polypeptide signal sequences of modified fragments of human immunoglobulin heavy chain binding protein (Bip) operably linked to a heterologous polypeptide and recovering the heterologous polypeptide.Type: ApplicationFiled: November 22, 2011Publication date: February 13, 2014Applicant: Callidus Biopharma, Inc.Inventor: Hung Do
-
Publication number: 20140046035Abstract: Anti-peptide antibodies (APAs) are extremely important tools for biomedical research. Many important techniques, such as immunoblots, ELISA immunoassays, immunocytochemistry, and protein microarrays are intrinsically linked to APA function and completely dependent on APA quality. Unfortunately, not all commercially-available APAs have good antigen binding characteristics; as a result, researchers are often unable to perform high quality protein analysis experiments. This disclosure describes a new method for the scalable production of polyclonal APAs using recombinant antigens. These recombinant peptide antigens have several advantages over traditional peptide antigens which improve the ease and speed of antibody production. The recombinant antigens can be scalably produced and purified much faster than traditional synthetic peptide-conjugates.Type: ApplicationFiled: November 29, 2011Publication date: February 13, 2014Applicant: BIOO SCIENTIFIC CORPORATIONInventors: Joseph Krebs, Paul Morrison, Jun Wang
-
Publication number: 20140045241Abstract: The present invention generally relates to immobilized enzymes for use in carbon capture and other systems; particularly, materials used to immobilize carbonic anhydrase are disclosed.Type: ApplicationFiled: March 8, 2012Publication date: February 13, 2014Applicant: Akermin, Inc.Inventors: Tracy Bucholz, Tizah Anjeh
-
Publication number: 20140044646Abstract: Disclosed are multivalent, integrin-receptor antagonists that are useful in a variety of therapeutic, prophylactic, and/or diagnostic imaging modalities. In illustrative embodiments, such compounds have been prepared and utilized in the imaging, detection, localization, and/or quantitation of one or more samples of biological interest. Similarly, these compounds, as well as formulations comprising them, find utility in the prevention, treatment, and/or amelioration of one or more symptoms of a disease, abnormal condition, dysfunction, etc., including, for example proliferative diseases such as cancer in affected animals. In certain embodiments, fluorescently- or radio-labeled-non-peptidic, multivalent integrin ?v?3 compounds are provided. Compositions including such compounds have been shown to have utility in detecting, localizing, quantitating, and/or imaging integrin ?v?3 receptor-expressing cells, including, for example, cancer cells in vitro, in vivo, and/or in situ.Type: ApplicationFiled: July 26, 2013Publication date: February 13, 2014Applicant: The Methodist Hospital Research InstituteInventors: King Chuen Li, Zheng Li, Feng Li
-
Publication number: 20140044773Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.Type: ApplicationFiled: May 7, 2013Publication date: February 13, 2014Inventor: Portola Pharmaceuticals, Inc.
-
Publication number: 20140044738Abstract: The present invention relates to antibodies and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to B7-H1 or PD-1. In some embodiments such molecules are additionally capable of modulating the ability of B7-H1 or B7-DC to bind to PD-1 or are capable of affecting the signaling activity of the B7-H1 or PD-1. The invention additionally concerns the uses of such molecules in the diagnosis and treatment of cancer and other diseases.Type: ApplicationFiled: April 19, 2012Publication date: February 13, 2014Applicant: AMPLIMMUNE, INC.Inventors: Solomon Langermann, Linda Liu, Shannon Marshall, Sheng Yao
-
Publication number: 20140045242Abstract: The present invention concerns methods and compositions for forming anti-cancer vaccine complexes. In preferred embodiments, the anti-cancer vaccine complex comprises an antibody moiety that binds to dendritic cells, such as an anti-CD74 antibody or antigen-binding fragment thereof, attached to an AD (anchoring domain) moiety and a xenoantigen, such as CD20, attached to a DDD (dimerization and docking domain) moiety, wherein two copies of the DDD moiety form a dimer that binds to the AD moiety, resulting in the formation of the vaccine complex. The anti-cancer vaccine complex is capable of inducing an immune response against xenoantigen expressing cancer cells, such as CD138negCD20+ MM stem cells, and inducing apoptosis of and inhibiting the growth of or eliminating the cancer cells.Type: ApplicationFiled: September 16, 2013Publication date: February 13, 2014Applicant: IBC PHARMACEUTICALS, INC.Inventors: Chien-Hsing Chang, David M. Goldenberg
-
Patent number: 8647620Abstract: The present invention relates to chimeric Factor VII polypeptides and methods of using the same.Type: GrantFiled: June 25, 2010Date of Patent: February 11, 2014Assignee: The University of North Carolina at Chapel HillInventors: Darrel W. Stafford, Dengmin Feng
-
Publication number: 20140037636Abstract: A human antibody or a functional fragment thereof having specific binding ability to CD98 which is derived from the cell membrane of cancer cells and is in the form of a complex with a protein having an amino acid transporter activity (for example, LAT1) is disclosed. This antibody binds to CD98 in the form of a dimer with LAT1 on the surface of cancer cells, specifically attacks cancer cells expressing CD98 via the immune system by ADCC or CDC, and further inhibits amino acid uptake of the cancer cells via LAT1, to suppress growth of the cancer cells. Accordingly, a preventive and therapeutic agent for cancer comprising this antibody or a fragment thereof, which acts on various cancers, is specific to cancer, and causes no side effect, is provided.Type: ApplicationFiled: July 12, 2013Publication date: February 6, 2014Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Tomoyuki TAHARA, Yoshikatsu KANAI, Hitoshi ENDOU, Shiro KATAOKA, Kazumasa HASEGAWA, Tetsuya YOSHINO
-
Publication number: 20140038255Abstract: The NonA alkene synthase in Synechococcus sp. displays selective synthesis of 1-nonadecene. Heterologous recombination of a domain, i.e. the acyl binding domain, with other acyl binding proteins, affects acyl substrate chain-length binding selectivity and therefore the chain-length of the synthesized 1-alkenes. Compositions and methods are provided to selectively synthesize 1-alkenes of various chain lengths.Type: ApplicationFiled: October 7, 2013Publication date: February 6, 2014Applicant: JOULE UNLIMITED TECHNOLOGIES, INC.Inventor: Christian Perry Ridley
-
Publication number: 20140037670Abstract: The invention is directed to means, based on CyaA-carried polypeptide(s), for use in the immunotherapeutic treatment of first determined pathological condition(s) diagnosed in a mammalian host by eliciting a T cell immune response against a first group of epitopes contained in said polypeptide(s) and in the prophylaxis against second determined pathological condition(s) in the same mammalian host by eliciting a T cell memory immune response against a second group of epitopes contained in said polypeptide(s), said immune responses being obtained after administration of said vector-carried polypeptide(s) into said host, wherein said prophylaxis against second determined pathological condition(s) is not observed when said second group of epitopes is not contained in said administered vector-carried polypeptide(s).Type: ApplicationFiled: January 24, 2012Publication date: February 6, 2014Applicant: GENTICELInventors: Michael EsquerrÉ, Marie Momot, Anne Goubier, Yolande Misseri
-
Publication number: 20140038886Abstract: The present invention relates to hydrophobic modified peptides for the specific delivery of compounds to the liver, preferably to hepatocytes, in vitro as well as in vivo. The present invention relates to pharmaceutical compositions comprising said hydrophobic modified peptide(s) and the compound(s) to be specifically delivered to the liver. The present invention furthermore relates to the use of the inventive hydrophobic modified peptides as well as to a method for the prevention and/or treatment of liver diseases or disorders.Type: ApplicationFiled: February 10, 2012Publication date: February 6, 2014Applicant: RUPRECHT-KARIS-UNVERSITAT HEIDELBERGInventors: Walter Mier, Stephan Urban, Stefan Mehrle, Uwe Haberkorn
-
Publication number: 20140038261Abstract: The present invention concerns methods and compositions for forming immunotoxin complexes having a high efficacy and low systemic toxicity. In preferred embodiments, the toxin moiety is a ranpirnase (Rap), such as Rap(Q). In more preferred embodiments, the immunotoxin is made using dock-and-lock (DNL) technology. The immunotoxin exhibits improved pharmacokinetics, with a longer serum half-life and significantly greater efficacy compared to toxin alone, antibody alone, unconjugated toxin plus antibody or even other types of toxin-antibody constructs. In a most preferred embodiment the construct comprises an anti-Trop-2 antibody conjugated to Rap, although other combinations of antibodies, antibody fragments and toxins may be used to form the subject immunotoxins. The immunotoxins are of use to treat a variety of diseases, such as cancer, autoimmune disease or immune dysfunction.Type: ApplicationFiled: September 4, 2013Publication date: February 6, 2014Applicants: IBC PHARMACEUTICALS, INC., IMMUNOMEDICS, INC.Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi
-
Publication number: 20140038241Abstract: By using engineered sequence specific DNA nuclease (“SSDN”), the composition, reagent kit and method of the present invention can cut and release a DNA sequence of interest 1×104-1×107-base pairs long from a source DNA as large as the whole genome. The SSDN further includes an affinity tag or is bound to a solid support that facilitates the isolation of the DNA sequence of interest. The SSDN can include a RecA and Ref combination, a transcription activator like effector nuclease, or a sequence specific chemical nuclease. When applied to genomic sequencing, specific region(s) of interest in the genome can be cut and isolated. Because the irrelevant part of the genome is removed from the sequencing reaction, the speed, cost, and accuracy of genomic sequencing can be improved.Type: ApplicationFiled: August 3, 2013Publication date: February 6, 2014Inventors: Zhaohui Zhou, Qun Shan
-
Patent number: 8642310Abstract: A hydrolytic enzyme is to be stabilized in a liquid surfactant preparation. This is achieved by using a component that stabilizes the hydrolytic enzyme and encompasses a phthaloylglutamic acid and/or a phthaloylaspartic acid.Type: GrantFiled: January 25, 2013Date of Patent: February 4, 2014Assignee: Henkel AG & Co. KGaAInventors: Petra Siegert, Marion Merkel, Hendrik Hellmuth, Timothy O'Connell, Karl-Heinz Maurer
-
Patent number: 8642283Abstract: The present invention provides an assay for the identification of agents which can modulate TOR-mediated phosphorylation of substrate proteins. The assays of the invention utilize substrate proteins whose amino acid sequence contains the Ser/Thr motif recognized by TOR. Naturally occurring TOR which may be used in the methods of the invention include TOR isolated from a variety of species, particularly mammalian tissues.Type: GrantFiled: May 26, 2006Date of Patent: February 4, 2014Assignee: Sanford-Burnham Medical Research InstituteInventor: Robert T. Abraham
-
Publication number: 20140030746Abstract: The disclosure relates to a cytoplasmic protein complex comprising: (a) a first recombinant fusion protein comprising a kinase, fused to a first interaction polypeptide; and (b) a second recombinant fusion protein comprising a domain comprising a reporter phosphorylation site, whereby the domain is fused to a second interaction polypeptide. The disclosure relates further to a method to detect compound-compound-interaction using the cytoplasmic protein complex, and to cells comprising such cytoplasmic protein complex.Type: ApplicationFiled: February 29, 2012Publication date: January 30, 2014Applicants: UNIVERSITEIT GENT, VIB VZWInventors: Jan Tavernier, Samuel Lievens
-
Publication number: 20140030273Abstract: Isolated human monoclonal antibodies which bind to human CD74 and related antibody-drug conjugates are disclosed. Pharmaceutical compositions comprising the antibodies or antibody-drug conjugates, and therapeutic and diagnostic methods for using the antibodies and/or antibody-drug conjugates, are also disclosed.Type: ApplicationFiled: February 1, 2012Publication date: January 30, 2014Applicant: GENMAB A/SInventors: Sandra Verploegen, Marije Overdijk, Riemke Van Dijkhuizen, Willem Karel Bleeker, Patrick Van Berkel, Paul Parren, Steen Lisby
-
Publication number: 20140030789Abstract: The present invention provides for a polyketide synthase (PKS) capable of synthesizing a dicarboxylic acid (diacid). Such diacids include diketide-diacids and triketide-diacids. The invention includes recombinant nucleic acid encoding the PKS, and host cells comprising the PKS. The invention also includes methods for producing the diacids.Type: ApplicationFiled: September 26, 2013Publication date: January 30, 2014Applicant: The Regents of the University of CaliforniaInventors: Leonard Katz, Jeffrey L. Fortman, Jay D. Keasling
-
Patent number: 8637009Abstract: Provided are compositions comprising a cocaine esterase (CocE) and a compound that thermostabilizes the CocE. Also provided are methods of thermostabilizing a cocaine esterase. Additionally provided are methods of treating a mammal undergoing a cocaine-induced condition. Methods of determining whether a compound is a thermostabilizing agent for a protein are also provided. Uses of the above-described compositions for the treatment of a cocaine-induced condition is additionally provided. Additionally provided is an isolated nucleic acid encoding a CocE polypeptide having the substitutions L169K and G173Q, and the CocE polypeptide encoded by that nucleic acid, and pharmaceutical compositions thereof. Further provided is the use of that composition for the manufacture of a medicament for the treatment of a cocaine-induced condition and for the treatment of a cocaine-induced condition.Type: GrantFiled: July 10, 2008Date of Patent: January 28, 2014Assignees: The Trustees of Columbia University in the City of New York, The Regents of the University of MichiganInventors: Donald W. Landry, James H. Woods, Roger K. Sunahara, Diwahar L. Narasimhan, Joanne MacDonald, Milan N. Stojanovich, John J. Tesmer, Remy L. Brim
-
Publication number: 20140024056Abstract: The present invention provides compounds that are surrogates of post-translationally modified proteins and uses thereof. Numerous diseases are associated with post-translationally modified proteins that are difficult to obtain in homogenous form and in quantities needed for immunization and use as convenient standards, calibrators, and/or reference compounds that facilitate the detection and analysis of endogenous post-translationally modified proteins. The surrogate compounds of the invention typically comprise antigenic epitopes (one of which carries a post-translational modification) that are tethered by a flexible and hydrophilic linker. The resulting compound behaves like a surrogate of the post-translationally modified protein because it preserves the character of the included antigens and allows recognition by specific antibodies targeting the individual antigens.Type: ApplicationFiled: February 10, 2012Publication date: January 23, 2014Applicant: President and Fellows of Harvard CollegeInventors: Michael Chorev, Joes A. Halperin
-
Publication number: 20140023628Abstract: The present invention provides a site-specific pegylated arginase conjugate and method for producing thereof. The site-specific pegylated arginase is homogeneous in molecular weight and shows therapeutic effect for treating cancers and viral infections. The method for producing the arginase conjugate comprises genetically modifying the gene encoding an arginase so that the PEG moiety can be attached to the enzyme at a predetermined, specific intended sites. This is achieved by removing the PEG-attaching amino acid residue(s) at undesirable site(s) while keeping or adding cysteine(s) at the desirable site(s) of the enzyme. Two exemplary embodiments of the pegylated arginase conjugate are directed to human arginase I (HAI) where a polyethylene glycol (PEG) moiety is site-specific covalently bonded to Cys45 of the enzyme and Bacillus caldovelox arginase (BCA) where a polyethylene glycol (PEG) moiety is site-specific covalently bonded to Cys161 of the enzyme.Type: ApplicationFiled: July 19, 2013Publication date: January 23, 2014Applicant: The Hong Kong Polytechnic UniversityInventors: Yun Chung LEUNG, Wai-hung LO
-
Publication number: 20140024089Abstract: The invention relates to recombinant expression of a taxadiene synthase enzyme and a geranylgeranyl diphosphate synthase (GGPPS) enzyme in cells and the production of terpenoids.Type: ApplicationFiled: July 17, 2013Publication date: January 23, 2014Applicant: Massachusetts Institute of TechnologyInventors: PARAYIL K. AJIKUMAR, GREGORY STEPHANOPOULOS, HENG PHON TOO
-
Publication number: 20140023592Abstract: A compound comprising three components A, B, and C, which components are covalently bound forming the compound having the structure A-B-C wherein component A has a specific binding affinity for antigens, component B is covalently linked to component A component C is a compound having an alkylated purine or pyrimidine moiety such as guanine, cytosine or a Coenzyme A moiety and linked thereto a moiety having a physiological effect with the proviso that component B has an catalytical or acceptor activity to couple component C with covalently coupled components A-B.Type: ApplicationFiled: September 30, 2013Publication date: January 23, 2014Applicants: RWTH Aachen, Fraunhofer-Gesellschaft zur Forderung der Angewandten Forschung e.V.Inventors: Markus Ribbert, Stefan Barth, Florian Kampmeier
-
Patent number: 8632975Abstract: Provided herein are compositions and systems for use in polymerase-dependent, nucleotide transient-binding methods. The methods are useful for deducing the sequence of a template nucleic acid molecule and single nucleotide polymorphism (SNP) analyses. The methods rely on the fact that the polymerase transient-binding time for a complementary nucleotide is longer compared to that of a non-complementary nucleotide. The labeled nucleotides transiently-binds the polymerase in a template-dependent manner, but does not incorporate. The methods are conducted under any reaction condition that permits transient binding of a complementary or non-complementary nucleotide to a polymerase, and inhibits nucleotide incorporation.Type: GrantFiled: May 28, 2010Date of Patent: January 21, 2014Assignee: Life Technologies CorporationInventors: Peter B. Vander Horn, Cheng-Yao Chen, Guobin Luo, Michael Previte, Jamshid Temirov, Theo Nikiforov, Zhaohui Zhou, Hongye Sun, Yufang Wang, Stefanie Yukiko Nishimura, Hongyi Wang, Marian Peris, Barnett B. Rosenblum, Michael Phelan
-
Publication number: 20140017224Abstract: The present invention relates to a polypeptide with endolysin activity comprising an amino acid sequence according to SEQ ID No. 1 and fragments or derivatives thereof, or fusion proteins derived thereof. Moreover, the present invention relates to nucleic acid molecules encoding said polypeptide or fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said polypeptide, fragment, derivative or fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means, as cosmetic substance or as sanitizing agent.Type: ApplicationFiled: November 3, 2011Publication date: January 16, 2014Applicants: UNIVERSITY OF MINHO, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&DInventors: Joana Cecilia Valente Rodrigues Azeredo, Silvio Roberto Branco Dos Santos, Leonardus Dorothea Kluskens, Rob Lavigne, Maarten Walmagh
-
Publication number: 20140017763Abstract: Proteases encompassing an amino acid sequence, which are at least 70% identical to the amino acid sequence specified in SEQ ID NO. 1 over the entire length thereof and which, in the listing according to SEQ ID NO. 1, have the amino acid substitution I21V in combination with at least one further amino acid substitution, the further amino acid substitution being selected from the group consisting of Q12L, M122L, N177V, A222S, V228I and T247N, and agents encompassing such proteases, exhibit very good cleaning performance on egg-containing stains.Type: ApplicationFiled: September 9, 2013Publication date: January 16, 2014Applicant: HENKEL AG & CO. KGAAInventors: Susanne Wieland, Petra Siegert, Timothy O'Connell, Karl-Heinz Maurer, Ronny Martinez, Ulrich Schwaneberg, Hendrik Hellmuth